These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 20107437)

  • 1. Metabolites in safety testing: "MIST" for the clinical pharmacologist.
    Frederick CB; Obach RS
    Clin Pharmacol Ther; 2010 Mar; 87(3):345-50. PubMed ID: 20107437
    [No Abstract]   [Full Text] [Related]  

  • 2. "Getting the dose right": facts, a blueprint, and encouragements.
    Peck CC; Cross JT
    Clin Pharmacol Ther; 2007 Jul; 82(1):12-4. PubMed ID: 17571068
    [No Abstract]   [Full Text] [Related]  

  • 3. Historical development of pediatric pharmacology.
    Seyberth HW; Rane A; Schwab M
    Handb Exp Pharmacol; 2011; 205():v-vi. PubMed ID: 22046631
    [No Abstract]   [Full Text] [Related]  

  • 4. Disease models.
    Gobburu J
    Clin Adv Hematol Oncol; 2008 Apr; 6(4):241-2. PubMed ID: 18496490
    [No Abstract]   [Full Text] [Related]  

  • 5. Drug safety and the role of clinical pharmacology in the safe use of therapeutics.
    Honig PK
    Clin Pharmacol Ther; 2009 Mar; 85(3):225-8. PubMed ID: 19223873
    [No Abstract]   [Full Text] [Related]  

  • 6. Issues in the safety testing of metabolites.
    Gross G; Wilson I
    Future Med Chem; 2009 Nov; 1(8):1381-90. PubMed ID: 21426053
    [No Abstract]   [Full Text] [Related]  

  • 7. Adolescents in clinical trials.
    Kapogiannis BG; Mattison DR
    Clin Pharmacol Ther; 2008 Dec; 84(6):655-9. PubMed ID: 19008903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effective global drug development strategy for obtaining regulatory approval in Japan in the context of ethnicity-related drug response factors.
    Ichimaru K; Toyoshima S; Uyama Y
    Clin Pharmacol Ther; 2010 Mar; 87(3):362-6. PubMed ID: 20107436
    [No Abstract]   [Full Text] [Related]  

  • 9. Institute of Medicine's new drug safety report: implications for Canada.
    Cassels A
    CMAJ; 2006 Dec; 175(12):1515-6. PubMed ID: 17146086
    [No Abstract]   [Full Text] [Related]  

  • 10. Seeing through the mist: abundance versus percentage. Commentary on metabolites in safety testing.
    Smith DA; Obach RS
    Drug Metab Dispos; 2005 Oct; 33(10):1409-17. PubMed ID: 15985503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Basic safety pharmacology: the cardiovascular system.
    Lacroix P; Provost D
    Therapie; 2000; 55(1):63-9. PubMed ID: 10860003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Therapeutics and clinical pharmacology of pediatric age].
    Stanulović M
    Srp Arh Celok Lek; 1995 Jun; 123 Suppl 1():1-4. PubMed ID: 18196639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenomics. Going from genome to pill.
    Service RF
    Science; 2005 Jun; 308(5730):1858-60. PubMed ID: 15976283
    [No Abstract]   [Full Text] [Related]  

  • 14. Prescription for trouble: common drugs, hidden dangers. Tens of people are at risk.
    Consum Rep; 2006 Jan; 71(1):34-9. PubMed ID: 16491527
    [No Abstract]   [Full Text] [Related]  

  • 15. Pharma's year of trouble and strife.
    Frantz S
    Nat Rev Drug Discov; 2006 Jan; 5(1):7-9. PubMed ID: 16485339
    [No Abstract]   [Full Text] [Related]  

  • 16. American College of Clinical Pharmacology position statement on the use of microdosing in the drug development process.
    Bertino JS; Greenberg HE; Reed MD;
    J Clin Pharmacol; 2007 Apr; 47(4):418-22. PubMed ID: 17389550
    [No Abstract]   [Full Text] [Related]  

  • 17. Why I love metabolites in safety testing (MIST): a light-hearted historical perspective.
    Tonelli A
    Bioanalysis; 2009 Jul; 1(4):683-5. PubMed ID: 21083127
    [No Abstract]   [Full Text] [Related]  

  • 18. Should we tolerate tolerability as an objective in early drug development?
    Cohen A
    Br J Clin Pharmacol; 2007 Sep; 64(3):249-52. PubMed ID: 17716332
    [No Abstract]   [Full Text] [Related]  

  • 19. [Clinical pharmacology from the standpoint of the pharmacologist].
    Rietbrock N
    Methods Find Exp Clin Pharmacol; 1981; 3 Suppl 1():17S-19S. PubMed ID: 7321656
    [No Abstract]   [Full Text] [Related]  

  • 20. Strategies for dealing with metabolite elucidation in drug discovery and development.
    Nassar AE; Talaat RE
    Drug Discov Today; 2004 Apr; 9(7):317-27. PubMed ID: 15037231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.